approved Eylea biosimilars. These include the following: Yesafili (aflibercept-jbvf) Opuviz (aflibercept-yszy) Pavblu (aflibercept-ayyh) Ahzantive (aflibercept-mrbb) Enzeevu (aflibercept-abzv) ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

Financial Hardship in Adolescent and Young Adult Oncology: The Need for Multidimensional and Multilevel Approaches The increased number and expanded utilization of biosimilars raise important ...

Opinions expressed are those of the author. Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and Neulasta. Humira now faces ...

Selarsdi, a human interleukin-12 and -23 antagonist, is currently indicated for: The FDA originally approved Selarsdi as a biosimilar for plaque psoriasis and psoriatic arthritis in April 2024 ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Biocon Biologics, a biosimilars company and subsidiary of Biocon Ltd, secured multiple market access agreements for Yesintek, a biosimilar to Stelara, used for the treatment of common chronic ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent ...